Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

August 19, 2022

Study Completion Date

October 3, 2025

Conditions
Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the Brain
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Ropidoxuridine

Given PO

RADIATION

Whole-Brain Radiotherapy

Undergo WBRT

Trial Locations (14)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

68198

University of Nebraska Medical Center, Omaha

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

77030

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston

Ben Taub General Hospital, Houston

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

92093

UC San Diego Moores Cancer Center, La Jolla

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH